References of "Delanaye, Pierre"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailKidney-Failure Risk Projection for the Living Kidney-Donor candidate.
DELANAYE, Pierre ULg; Glassock, Richard

in New England Journal of Medicine (2016), 374(21), 2093-2094

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailCystatin C standardization decreases assay variation and improves assessment of glomerular filtration rate
Ebert, N; DELANAYE, Pierre ULg; Shlipak, M et al

in Clinica Chimica Acta (2016), 456

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailConcordance between Iothalamate and Iohexol Plasma Clearance
DELANAYE, Pierre ULg; LE GOFF, Caroline ULg; JOURET, François ULg et al

in American Journal of Kidney Diseases (2016)

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailBone disease after kidney transplantation
BOUQUEGNEAU, Antoine ULg; Salam, Syrazah; DELANAYE, Pierre ULg et al

in Clinical Journal of the American Society of Nephrology (2016), 11(7), 1282-1296

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailCystatin C standardization decreases assay variation and improves assessment of GFR
Ebert, N; DELANAYE, Pierre ULg; Shlipak, M et al

Poster (2016)

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailAn estimated glomerular filtration rate equation for the full age spectrum
Pottel, H; Hoste, L; Dubourg, L et al

in Nephrology Dialysis Transplantation (2016), 31(5), 798-806

Detailed reference viewed: 22 (6 ULg)
Full Text
Peer Reviewed
See detailCreatinine-based equations for the adjustment of drug dosage in an obese population.
BOUQUEGNEAU, Antoine ULg; Vidal-Petiot, E; Moranne, O et al

in British Journal of Clinical Pharmacology (2016), 81(2), 349-361

Detailed reference viewed: 28 (14 ULg)
Full Text
Peer Reviewed
See detailAn age-calibrated definition of chronic kidney disease: Rationale and benefits.
DELANAYE, Pierre ULg; Glassock, Richard; Pottel, H et al

in Clinical Biochemist. Reviews (2016), 37(1),

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailEfficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Fafin, Coraline et al

in Journal of Nephrology (2016), 29(1), 99-103

Introduction Adherence to therapy is a relevant challenge in chronic hemodialysis patients. The directly observed therapy (DOT) could be an effective method to increase adherence for specific therapies ... [more ▼]

Introduction Adherence to therapy is a relevant challenge in chronic hemodialysis patients. The directly observed therapy (DOT) could be an effective method to increase adherence for specific therapies. We aimed to study the performance of DOT versus home medication. We follow the impact of providing native vitamin D directly by the nurse after a dialysis session on the 25-hydroxyvitamin [25(OH)D] concentrations. Methods In this observational study, we included 38 dialysis patients treated by stable dosage of cholecalciferol. DOT was implemented in December 2010. We considered the concentrations of 25-OH vitamin D three times before (T1 = June 2010, T2 = July 2010 and T3 = September 2010) and three times after the modification of prescription (T4 = February 2011, T5 = March 2011 and T6 = April 2011). Results Median age was 72 [62; 79] years and 48 % were diabetics. Mean body mass index was 26 ± 5 kg/m2 and median dialysis vintage was 20 [8; 46] months. The patients were compared to themselves. Before DOT, median concentrations of 25(OH)D were 27 (14–36), 23 (17–31), 31 (22–38) ng/mL at T1, T2 and T3, respectively. When DOT was effective, the concentrations significantly increased to 34 (28–44), 35 (29–41), 39 (32–47) ng/mL at T4, T5 and T6, respectively. Before DOT, 19 patients (50 %) reached the target of 30 ng/mL. After DOT, 29 patients (76 %) reached the target concentration of 30 ng/ mL. Conclusions In hemodialysis patients, DOT is both simple and effective to increase the therapeutic impact to native vitamin D. [less ▲]

Detailed reference viewed: 30 (12 ULg)
Full Text
Peer Reviewed
See detailConcordance between iohexol and iothalamate plasma clearance
DELANAYE, Pierre ULg; JOURET, François ULg; LE GOFF, Caroline ULg et al

in American Journal of Kidney Diseases (2016)

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailReference Method and Reference Material Are Necessary Tools to Reveal the Variability of Cystatin C Assays
Bargnoux, Anne-Sophie; Kuster, Nils; Delatour, Vincent et al

in Archives of Pathology & Laboratory Medicine (2016), 140(2), 117-118

Detailed reference viewed: 43 (4 ULg)
Full Text
Peer Reviewed
See detailAdaptation posologique des médicaments et fonction rénale : Quel(s) estimateur(s) faut-il choisir?
DELANAYE, Pierre ULg; Flamant, M; CAVALIER, Etienne ULg et al

in Néphrologie & Thérapeutique (2016), 12(1), 18-31

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations ... [more ▼]

Le choix de la formule d’estimation du de´ bit de filtration glomérulaire (DFG) a` utiliser pour l’adaptation posologique fait encore de´ bat, principalement entre la formule de Cockcroft et les équations plus récentes, MDRD (pour Modified Diet in Renal Disease) et CKD-EPI (pour Chronic Kidney Disease Epidemiology). Les arguments mis en avant en faveur de l’utilisation de la formule de Cockcroft sont : qu’elle a été préférentiellement utilisée pour décider des adaptations posologiques avant la mise sur le marché des médicaments, qu’elle permettrait une meilleure prédiction du risque de survenue des effets indésirables a` l’accumulation des médicaments, qu’elle permettrait de limiter le surdosage médicamenteux chez la personne âgée. Dans cet article d’opinion, nous discutons les faiblesses de l’argumentaire des partisans du maintien de l’utilisation de la formule de Cockcroft dans le contexte de l’adaptation posologique, ainsi que les limites et le manque de fiabilité de cette formule. Nous soutenons la recommandation de la Haute Autorité de sante´ (HAS) sur l’utilisation systématique, en 2015, de l’équation CKD-EPI pour l’estimation du DFG. Lorsque le DFG est e´ value´ dans le but d’adapter la posologie d’un médicament, la désindexation de la surface corporelle est préférable. Compte tenu des difficultés d’estimation du DFG chez la personne âgée et chez les individus a` gabarit hors norme, nous recommandons d’utiliser en priorité dans ces populations, des médicaments pour lesquels un suivi pharmacologique est disponible, ou d’avoir recours à une méthode de référence de mesure du DFG. [less ▲]

Detailed reference viewed: 35 (3 ULg)